Table 1 Summary of microbial challenged animal models tes5ng an NAD metabolite treatment.
Author (year) | Country | Animal | Microbe or microbial toxin challenge | Treatment type | Treatment time | Category of measures analyzable from studies* |
|---|---|---|---|---|---|---|
Abdel Rasheed (2023)29 | Egypt | Mouse | LPS (type: E. Coli) | Niacin | D0 | Organ injury; cytokines |
BeJenworth (2014)19 | Germany, US | Mouse | Citrobacter roden0um | NAM | Pre | Microbial clearance; organ injury; MPO |
Cao (2023)30 | China, UK, US | Mouse | Feces | NMN | D0 | Survival; microbial clearance; organ injury; cytokines; oxidants; MPO |
Chang (1954)31 | US | Mouse | Mycobacterium lepraemurium | NAM | D0 or Post | Survival |
Cros (2022)22 | France, Switzerland | Mouse | CLP | NMN | D0 | NAD metabolites; survival; microbial clearance |
Doganay (2022)32 | Turkey | Rat | CLP | NAM | Pre | Cytokines; anZoxidants |
Du (2022)33 | China | Mouse | LPS (type: E. Coli) | NMN | Pre | NAD metabolites; survival; organ injury; oxidants; anZoxidants |
Duan (2023)34 | Korea | Mouse | CLP | NAM, NR, Niacin | D0 | Survival |
Fernandes (2011)20 | Belgium | Mouse | LPS (type: E. Coli) | NAM | D0 | Organ injury |
Fukuzawa (1997)35 | Japan | Mouse | LPS (type: E. Coli) | NAM | D0 | Cytokines |
Fulton (1974)36 | US | Rat | LPS (type: E. Coli) | NAM | D0 | Survival |
Griesman (1979)37 | US | Mouse | Proteus mirabilis | NAM, Niacin | D0 | Survival |
Guo, W. (2020)38 | China | Cows | Mastitis (endogenous) | Niacin | Post | Cytokines |
Guo, W. (2021)39 | China | Mouse | LPS (type: UC) | Niacin | Pre | Organ injury; cytokines; MPO |
Han (2003)40 | US | Mouse | LPS (type: E. Coli) | NAD+ | D0 | Organ injury |
He, D. (2023)41 | China | Mouse | LPS (type: UC) | NAM, NR, Niacin | D0 | Survival |
He, M. (2016)42 | South Korea | Mouse | KSHV | NAM | Post | Survival |
He, S. (2022)11 | China | Mouse | LPS (type: E. Coli) | NMN | Pre | NAD metabolites; organ injury |
He, S. (2024)12 | China | Mouse | LPS (type: E. Coli) | NMN | D0 | NAD metabolites; organ injury; MPO |
Hilton (1976)43 | US | Dog | LPS (type: E. Coli) | Niacin | D0 | Survival |
Hong (2018)21 | Canada, China, US | Mouse | Feces or LPS (type: UC) | NR | D0 | Survival; organ injury; oxidants; MPO |
Imaruoka (2019)44 | Japan | Mouse | LPS (type: UC) | NAM | Pre | Organ injury; cytokines |
Iske (2024)45 | China, Germany, Switzerland, US | Mouse | LPS (type: E. Coli) or E. coli 0111:B4 | NAD+ | Pre | Survival; organ injury; microbial clearance; cytokines |
Izadpanah (2023)46 | US | Mouse | SARS-CoV-2 | NR | D0 | NAD metabolites |
Jiang (2022)13 | China | Mouse | SARS-CoV-2 | NAD+ | D0 | NAD metabolites; survival; organ injury; microbial clearance |
Kao (2007)47 | Taiwan | Rat | LPS (type: E. Coli) | NAM | D0 | Organ injury; cytokines |
Kwon, W.Y. (2011)14 | South Korea | Rat | LPS (type: E. Coli) | Niacin | D0 | NAD metabolites; survival; organ injury; cytokines; oxidants; anZoxidants |
Kwon, W.Y. (2016)48 | South Korea | Rat | LPS (type: E. Coli) or CLP | Niacin | D0 | Survival; organ injury; cytokines; oxidants; anZoxidants |
LeClaire (1996)49 | USA | Mouse | SEB and LPS (type: E. Coli) | NAM | D0 | Survival; cytokines |
Li, W. (2016)50 | China | Mouse | HBV (endogenous) | NAM | D0 | Microbial clearance |
Li, H.R. (2023)15 | China | Mouse | CLP | NMN | D0 | NAD metabolites; survival; cytokines; oxidants; anZoxidants |
Liu (2024)51 | China | Mouse | LPS (type: UC) | NMN | Pre | Cytokines |
Micheva-Viteva (2019)52 | USA | Mouse | Burkhoderia. pseudomallei | NAM | Pre | Survival |
Mo (2023)53 | China | Mouse | Human immuno-deficiency virus-1 (HIV-1) | NMN | D0 | NAD metabolites; microbial clearance |
Nagai (1994)16 | Japan | Hamster | LPS (type: UC) | Niacin | D0 | NAD metabolites; survival; organ injury |
Pacl (2023)54 | South Africa, US | Mouse | Mycobacterium tuberculosis | NAM | Post | Organ injury; microbial clearance |
Park (2023)55 | Korea | Rat | CLP | Niacin | D0 | Survival; organ injury; cytokines; oxidants; MPO |
Pulido (1999)56 | USA | Rat | LPS (type: S. typhimurium) | NAM | D0 | Organ injury; MPO |
Roboon (2021)17 | Japan, USA | Mouse | LPS (type: UC) | NR | Pre | NAD metabolites; cytokines |
Rodriguez (2018)57 | Germany, India, Spain, Switzerland, US | Mouse | Listeria monocytogenes | NAD+ | Pre | Survival |
Scharte (2003)58 | Germany | Sheep | LPS (type: S. typhosa) | NAM | D0 | Organ injury |
Selli (2023)59 | Turkey | Rat | CLP | NR | D0 | Oxidants; anZoxidants; MPO |
Shaw (1966)60 | USA | Rat | LPS (type: E. Coli) | NAM | D0 | Survival |
Shi (2017)61 | China, US | Mouse | LPS (type: UC) | Niacin | D0 | Cytokines |
Smith (1977)62 | USA | Mouse | Staphylococcus aureus | NAM | D0 | Survival |
Tian (2023)63 | China | Mouse | LPS (type: UC) | NMN | UC | Organ injury; cytokines; oxidants; anZoxidants |
Umapathy (2012)64 | USA | Mouse | LPS (type: UC) | NAD+ | D0 | Organ injury; cytokines; MPO |
Wray (1998)65 | UK | Rat | LPS (type: E. Coli) | NAM | D0 | Survival; organ injury |
Wurtele (2010)66 | Canada | Mouse | Candida albicans | NAM | D0 | Microbial clearance |
Xing (2019)67 | China | Mouse | Candida albicans | NAM | D0 | Survival |
Xu (2014)68 | China | Rat | CLP | NAM | Pre | Organ injury, cytokines; oxidants |
Yan (2022)69 | China | Mouse | Candida albicans | NAM | D0 | Survival; microbial clearance |
Ye (2022)70 | US | Mouse | LPS (type: E. Coli) or CLP | NAD+ | D0 | Survival; organ injury; cytokines |
Yuan (2012)71 | China | Mouse | LPS (type: E. coli) + /- D-Gal or CLP | NAM | D0 | Survival; organ injury; cytokines |
Zhao (2023)72 | China | Mouse | CLP | NR | D0 | NAD metabolites; survival; organ injury; cytokines |
Zingarelli (1996)73 | USA | Rat | LPS (type: E. Coli) | NAM | D0 | NAD metabolites |
